Search Results

Return to List
Results 21–37 of 37
Title Date
21.

OnabotulinumtoxinA and the Bladder

Number 604

ABSTRACT In January 2013 the US Food and Drug Administration approved the use of onabotulinumtoxinA also known as Botox A for the treatment of overactive bladder thus providing another treatment option for women Symptoms of overactive bladder have been shown to significantly improve after onabotul...

June 2014

PDF Format
22.

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Number 606

ABSTRACT Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding and gynecologists may be consulted either before the initiation of cancer treatment to request strategies for menstrual suppression or during an episode of severe heavy bleeding to stop the bleeding emerg...

August 2014

PDF Format
23.

Ovarian Reserve Testing

Number 618

ABSTRACT The main goal of ovarian reserve testing is to identify those individuals who are at risk of decreased or diminished ovarian reserve commonly known as DOR Although ovarian reserve testing cannot predict the end of ones reproductive years results outside the range expected for a patients a...

January 2015

PDF Format
24.

Over-the-Counter Access to Oral Contraceptives

Number 544

(Reaffirmed 2014)

ABSTRACT Unintended pregnancy remains a major public health problem in the United States Access and cost issues are common reasons why women either do not use contraception or have gaps in use A potential way to improve contraceptive access and use and possibly decrease unintended pregnancy rates ...

December 2012

PDF Format
25.

Pain Relief During Labor

Number 295

(Reaffirmed 2008, Replaces No. 231, February 2000)

ABSTRACT Pain management should be provided whenever medically indicated The American Society of Anesthesiologists ASA and the American College of Obstetricians and Gynecologists ACOG believe that women requesting epidural analgesia during labor should not be deprived of this service based on thei...

July 2004

PDF Format
26.

Pharmacogenetics

Number 488

(Reaffirmed 2015)

ABSTRACT Pharmacogenetics is the study of genetic variations in drug response that are determined by specific genes It is hoped that the use of pharmacogenetics in clinical practice may improve drug safety and decrease the rate of adverse drug reactions Given the potential applications of pharmaco...

May 2011

PDF Format
27.

Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism

Number 556

(Reaffirmed 2015)

ABSTRACT The development of menopausal symptoms and related disorders which lead women to seek prescriptions for postmenopausal estrogen therapy and hormone therapy is a common reason for a patient to visit her gynecologist but these therapies are associated with an increased risk of venous thromb...

April 2013

PDF Format
28.

Preexposure Prophylaxis for the Prevention of Human Immunodeficiency Virus

Number 595

Abstract Preexposure prophylaxis is defined as the administration of antiretroviral medications to individuals who are not infected with human immunodeficiency virus HIV and are at the highest risk of acquiring HIV infection In combination with other proven HIVprevention methods preexposure prophy...

May 2014

PDF Format
29.

Prevention of Early-Onset Group B Streptococcal Disease in Newborns

Number 485

(Replaces No. 279, December 2002, Reaffirmed 2015)

ABSTRACT In 2010 the Centers for Disease Control and Prevention revised its guidelines for the prevention of perinatal group B streptococcal disease Although universal screening at 3537 weeks of gestation and intrapartum antibiotic prophylaxis continue to be the basis of the prevention strategy th...

April 2011

PDF Format
30.

Primary Ovarian Insufficiency in Adolescents and Young Women

Number 605

ABSTRACT Primary ovarian insufficiency is the depletion or dysfunction of ovarian follicles with cessation of menses before age 40 years There is no consensus on criteria to identify primary ovarian insufficiency in adolescents and delay in diagnosis is common Health care providers who make this c...

July 2014

PDF Format
31.

Professional Relationships With Industry

Number 541

(Replaces No. 401, March 2008)

ABSTRACT The American College of Obstetricians and Gynecologists the College has a long history of leadership in ensuring that its educational mission is evidence based and unbiased A predecessor to this Committee Opinion was published in 1985 making the College one of the first professional assoc...

November 2012

PDF Format
32.

Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

Number 540

(Reaffirmed 2014)

ABSTRACT Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones and some data have suggested that use of drospirenonecontaining pills has a higher risk of venous thromboembolism this risk is still ...

November 2012

PDF Format
33.

Solutions for Surgical Preparation of the Vagina

Number 571

ABSTRACT Currently only povidoneiodine preparations are approved for vaginal surgicalsite antisepsis However there are compelling reasons to consider chlorhexidine gluconate solutions for offlabel use in surgical preparation of the vagina especially in women with allergies to iodine Although chlor...

September 2013

PDF Format
34.

Sulfonamides, Nitrofurantoin, and Risk of Birth Defects

Number 494

Reaffirmed 2013

Abstract The evidence regarding an association between the nitrofuran and sulfonamide classes of antibiotics and birth defects is mixed As with all patients antibiotics should be prescribed for pregnant women only for appropriate indications and for the shortest effective duration During the secon...

June 2011

PDF Format
35.

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT Tamoxifen a nonsteroidal antiestrogen agent is widely used as adjunctive therapy for women with breast cancer and it has been approved by the US Food and Drug Administration for adjuvant treatment of breast cancer treatment of metastatic breast cancer and reduction in breast cancer incide...

June 2014

PDF Format
36.

Update on Immunization and Pregnancy Tetanus Diphtheria and Pertussis Vaccination

Number 566

(Replaces No. 521, March 2012, Reaffirmed 2015)

ABSTRACT In the face of dramatic and persistent increases in pertussis disease in the United States the Centers for Disease Control and Preventions Advisory Committee on Immunization Practices has updated its guidelines for the use of the tetanus toxoid reduced diphtheria toxoid and acellular pert...

June 2013

PDF Format
37.

Vitamin D: Screening and Supplementation During Pregnancy

Number 495

ABSTRACT During pregnancy severe maternal vitamin D deficiency has been associated with biochemical evidence of disordered skeletal homeostasis congenital rickets and fractures in the newborn At this time there is insufficient evidence to support a recommendation for screening all pregnant women f...

July 2011

PDF Format

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998